NDC 17856-0672-01 - Ondansetron
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 17856-0672
- Requested NDC
- 17856-0672-01
- Package NDCs from labels
- 17856-0672-1, 17856-0672-2, 17856-0672-3, 17856-0672-4, 17856-0672-01
- Manufacturer
- Atlantic Biologics Corp.
- Effective date
- 2025-10-23
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Ondansetron - Atlantic Biologics Corp. | Atlantic Biologics Corp. | 2025-10-23 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-0672-1 | Ondansetron | 60 in 1 CASE | SOLUTION | 60 | 1 | |
| 17856-0672-1 | Ondansetron | 2.5 mL in 1 SYRINGE | SOLUTION | 2.5 | 1 | |
| 17856-0672-2 | Ondansetron | 120 in 1 CASE | SOLUTION | 120 | 1 | |
| 17856-0672-2 | Ondansetron | 2.5 mL in 1 SYRINGE | SOLUTION | 2.5 | 1 | |
| 17856-0672-3 | Ondansetron | 120 in 1 CASE | SOLUTION | 120 | 1 | |
| 17856-0672-3 | Ondansetron | 2.5 mL in 1 SYRINGE | SOLUTION | 2.5 | 1 | |
| 17856-0672-4 | Ondansetron | 72 in 1 CASE | SOLUTION | 72 | 1 | |
| 17856-0672-4 | Ondansetron | 5 mL in 1 CUP, UNIT-DOSE | SOLUTION | 5 | 1 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 17856-0672-1 | ML - Milliliter | 17856-0672 | f5b97fd9-6050-46e6-b0da-693821d3938a | 1 | 2026-03-17 |
| 17856-0672-2 | ML - Milliliter | 17856-0672 | 787cc894-2cc2-4952-981c-f67609a087e3 | 1 | 2026-03-17 |
| 17856-0672-3 | ML - Milliliter | 17856-0672 | 53831650-5a50-4e31-9590-1c0ac60dc7ec | 1 | 2026-03-17 |
| 17856-0672-4 | ML - Milliliter | 17856-0672 | 68c3eadb-fcbb-40cc-80d0-0ddc4021b83a | 1 | 2026-02-05 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| REFRESH OPTIVE | CARBOXYMETHYLCELLULOSE SODIUM AND GLYCERIN | Allergan, Inc. | 7f8d88af-fd3b-4138-af61-f24c59ccebd7 | 2022-09-23 | Warnings | PDC6A3C0OX |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | ebd0839e-2e1d-4e0e-986c-19f1f5c76358 | 2022-09-15 | Warnings | PDC6A3C0OX |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, AND POLYSORBATE 80 | Allergan, Inc. | aaa943e4-7c38-4c5a-b7c0-5a656d8cafc0 | 2022-09-01 | Warnings | PDC6A3C0OX |
| Glycerinum | GLYCERINUM | Hahnemann Laboratories, INC. | e34f8796-85b5-2946-e053-2995a90a251e | 2022-07-08 | PDC6A3C0OX | |
| REFRESH Optive Mega-3 | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 | Allergan, Inc. | c5f2b3f2-2071-45bd-a010-67f848bc0233 | 2022-06-30 | Warnings | PDC6A3C0OX |
| Addiclenz | BETA VULGARIS, BOLDO, CHELIDONIUM MAJUS, PETROSELINUM SATIVUM, TARAXACUM OFFICINALE, ARSENICUM ALBUM, BISPHENOL A, COBALTUM METALLICUM, CUPRUM METALLICUM, GLYPHOSATE, IODIUM, LYCOPODIUM CLAVATUM, PHOSPHORICUM ACIDUM, SELENIUM METALLICUM, ZINCUM METALLICUM, ASPARTAME, BENZALKONIUM CHLORIDE, FORMALINUM, METHYLENE CHLORIDE, METHYL PARABEN, PROPYL PARABEN, SODIUM BENZOATE, SODIUM CITRATE, TITANIUM DIOXIDE, ZINCUM OXYDATUM | Deseret Biologicals, Inc. | e39235ea-2a2f-44a7-92d6-fb1d428ebabd | 2022-05-12 | Warnings | OJ245FE5EU |
| Ondansetron Hydrochloride | ONDANSETRON HYDROCHLORIDE | Proficient Rx LP | 69ed01b7-a94e-4946-a044-a9f8c37616ec | 2022-05-02 | Warnings, Adverse reactions | NMH84OZK2B |
| ACD Blood-Pack Units (PL 146 PLASTIC) | ANTICOAGULANT CITRATE DEXTROSE (ACD) | Fenwal, Inc. | ba894daa-688e-4a9e-bd74-e71797f951bb | 2022-04-27 | XF417D3PSL B22547B95K | |
| Ondansetron Hydrochloride | ONDANSETRON HYDROCHLORIDE | Proficient Rx LP | 381b44e7-a5a1-42ad-bcea-1ab4c82ff5d4 | 2022-04-01 | Warnings, Adverse reactions | NMH84OZK2B |
| Miracle FootCream Lavender | UREA, GLYCERIN, ALOE, DISODIUM EDTA | Aloe Vera Korea Co.,Ltd. | db520c80-2a2a-5eb1-e053-2995a90a5bb4 | 2022-03-28 | Warnings | 7FLD91C86K PDC6A3C0OX |
| Miracle FootCream Lemon | UREA, GLYCERIN, ALOE, DISODIUM EDTA | Aloe Vera Korea Co.,Ltd. | db525c63-29fd-2033-e053-2995a90a56b9 | 2022-03-28 | Warnings | 7FLD91C86K PDC6A3C0OX |
| ONDANSETRON | ONDANSETRON | Qilu Pharmaceutical Co., Ltd. | 5e09e262-dadf-4ae0-825e-448ea8dac174 | 2022-03-02 | Warnings, Adverse reactions | NMH84OZK2B |
| Sodium Citrate Blood-Pack Units, (PL 146 Plastic) | ANTICOAGULANT SODIUM CITRATE SOLUTION | Fenwal, Inc. | a63da38d-1fea-4ee0-a70b-55c891a5ebcc | 2022-02-11 | B22547B95K | |
| Sodium Citrate Blood-Pack Units, (PL 146 Plastic) | ANTICOAGULANT SODIUM CITRATE SOLUTION | Fenwal, Inc. | ac8971a9-36d0-43c9-9121-ba5e58c28bed | 2022-02-11 | B22547B95K | |
| ACD-A | ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A | Fenwal, Inc. | 22805f0d-ba58-41ea-b245-19980abcda22 | 2022-02-11 | XF417D3PSL | |
| TH-101 | CALC CARB, CARBO VEG, CHELIDONIUM MAJ, COQ10, FUCUS, GRAPHITES, HOMEOPATHIC GLYCOPROTEIN COMPLEX, HYPOTHALAMUS, KALI PHOS, LYCOPODIUM, MAG PHOS, NAT MUR, NAT PHOS, NUX VOM, ORNITHOGALUM, PHYTOLACCA, PITUITARUM, PLACENTA, SINAPIS ARV FLOS, QUERCUS GLAND SP, QUERCUS ROB | Temple Health Nutrition, LLC | d54bb860-560c-4f8f-9aea-a0b7774cc92b | 2021-12-29 | Warnings | C151H8M554 |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | d763511e-f1a7-4014-94b9-f7ad8f023ff4 | 2021-12-02 | XF417D3PSL B22547B95K | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | cf9f43a0-c750-4cf0-ac49-176ab2105aab | 2021-12-02 | XF417D3PSL B22547B95K | |
| Ondansetron | ONDANSETRON TABLETS | Natco Pharma Limited | 59c817b7-a1c6-48a5-9bfc-2c381532bfd9 | 2021-11-29 | Warnings, Adverse reactions | NMH84OZK2B |
| InterSol | PLATELET ADDITIVE 3 | Fenwal, Inc. | e4f06c0b-7cb1-49c9-97a4-2cfc21298495 | 2021-11-16 | Warnings, Adverse reactions | B22547B95K |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.